HASEGAWA Kosei

Affiliation and department：
Job title： Professor
Homepage URL (1)： http://www.saitama-med.ac.jp/kokusai/fujinshuyo/
Research theme for competitive and other funds (6)：

2016 - 現在卵巣明細胞腺癌におけるネオ抗原および局所免疫応答の統合的解析
2019 - 2023 卵巣癌の個別化治療を目指した免疫プロファイルに基づく包括的バイオマーカーの開発
2020 - 2021 ヒト上皮性腫瘍の発生・進展機構の解明と新規治療標的の同定
2018 - 2021 卵巣癌における、低酸素関連因子の発現からみた組織型の意義:科学療法抵抗性の分別化
2020 - 抗レトロウィルス薬のドラッグリバーバシングによるLINE1発現子宮体癌の治療戦略

Show all

Papers (90)：

Ishida M, Sato S, Sato I, Yoshioka A, Uchida N, Mizunuma N, Hasegawa K, Onishi H. What can cause cancer patients to attempt suicide? Thiamine deficiency mimicking the symptoms of major depressive disorder. Palliat Support Care. 2024
Tewari KS, Colombo N, Monk BJ, Dubot C, Cáceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüs M, et al. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial. JAMA Oncol. 2024
Yonemori K, Fujiwara K, Hasegawa K, Yunokawa M, Ushijima K, Suzuki S, Shikama A, Minobe S, Usami T, Kim JW, et al. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. JGO. 2024
Colombo N, Lorusso D, Monk BJ, Slomovitz B, Hasegawa K, Nogueira-Rodrigues A, Zale M, Okpara CE, Barresi G, McKenzie J, et al. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab. Oncologist. Oncologist. 2024
Isoda L, Sonoda-Fukuda E, Fujino H, Takarada T, Hasegawa K, Kasahara N, Kubo S. Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer. Anticancer Res. 2023

ｍore...

Lectures and oral presentations (24)：

HDAC6 as a therapeutic target for ovarian clear cell carcinoma, in association with ARID1A loss
(17th Biennial Meeting of the International Gynecologic Cancer Society 2018)
Soluble folate receptor alpha as a biomarker for epithelial ovarian cancer
(72th Japanese Cancer Association 2013)
Redirected antitumor activity of an engineered Sendai virus vector in ovarian cancer cells
(AACR/JCA 2013)
Tumor Board I: Clear cell carcinoma of the uterus
(14th Biennial Meeting of the International Gynecologic Cancer Society 2012)
Soluble MUC1 as a Biomarker for Epithelial Ovarian Cancer
(14th Biennial Meeting of the International Gynecologic Cancer Society 2012)

ｍore...

Education (2)：

2000 - 2004 Okayama University Graduate School, Division of Medicine
1991 - 1997 Okayama University Graduate School, Division of Medicine

Professional career (2)：

医学士 (岡山大学)
医学博士 (岡山大学大学院)

Work history (8)：

2006/10 - 2008/09 University of Pennsylvania Ovarian Cancer Research Center Researher Postdoc
2006/10 - 2008/09 University of Pennsylvania Ovarian Cancer Research Center Researcher
2006/10 - 2008/09 University of Pennsylvania Ovarian Cancer Research Center Researcher
2004/09 - 2006/09 Mayo Clinic Department of Molecular Medicine Researher Postdoc
2004/09 - 2006/09 Mayo Clinic Department of Molecular Medicine Researcher

Show all

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page